Showing results (21-30 of 29) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 29 results.
British Journal of Cancer|August 1, 2019
EZH2 cooperates with E2F1 to stimulate expression of genes involved in adrenocortical carcinoma aggressivenessHouda Tabbal, Amandine Septier, Mickael Mathieu, et al.
Human Molecular Genetics|May 7, 2016
EZH2 is overexpressed in adrenocortical carcinoma and is associated with disease progressionCoralie Drelon, Annabel Berthon, Mickael Mathieu, et al.
Human Molecular Genetics|October 3, 2013
WNT/β-catenin signalling is activated in aldosterone-producing adenomas and controls aldosterone productionAnnabel Berthon, Coralie Drelon, Bruno Ragazzon, et al.
Nature Communications|September 15, 2016
PKA inhibits WNT signalling in adrenal cortex zonation and prevents malignant tumour developmentCoralie Drelon, Annabel Berthon, Isabelle Sahut-Barnola, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 14, 2018
Steroidogenic differentiation and PKA signaling are programmed by histone methyltransferase EZH2 in the adrenal cortexMickael Mathieu, Coralie Drelon, Stéphanie Rodriguez, et al.
European Journal of Nuclear Medicine and Molecular Imaging|December 6, 2023
Performance of [18F]fluorocholine PET/CT in MEN1-related primary hyperparathyroidism before initial surgery or for persistent/recurrent diseaseAymeric Boucher, Julia Delabie, Charlotte Lussey-Lepoutre, et al.
The Journal of Clinical Endocrinology and Metabolism|December 23, 2021
Value of Somatostatin Receptor PET/CT in Patients With MEN1 at Various Stages of Their DiseaseClément Mennetrey, Maëlle Le Bras, Aurélie Bando-Delaunay, et al.
Thyroid : Official Journal of the American Thyroid Association|October 19, 2023
Factors Associated with Survival in Anaplastic Thyroid Carcinoma: A Multicenter Study from the ENDOCAN-TUTHYREF NetworkArnaud Jannin, Fabiola Giudici, Christelle de la Fouchardière, et al.
European Journal of Endocrinology|April 23, 2017
Temozolomide treatment can improve overall survival in aggressive pituitary tumors and pituitary carcinomasHélène Lasolle, Christine Cortet, Fréderic Castinetti, et al.
Pageof 3